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Background. Radiation-induced sarcomas are well-known potential late sequelae of radiation therapy. They are of rare occurrence
in jaw bones and are even rarer in the maxilla. Case report. We report a case of radiation-induced osteosarcoma involving the
maxilla in a patient treated with radiotherapy for nasopharyngeal carcinoma 14 years ago. Despite neoadjuvant chemotherapy,
surgical treatment could not be performed, and the patient received palliative chemotherapy. Conclusions. Radiation-induced
osteosarcomas are aggressive and often elude early detection and timely intervention, rapidly leading to early demise of aﬄicted
patients. Long-term patient follow-up and a high index of suspicion are crucial for timely intervention.
Copyright © 2009 Imene Chabchoub et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
Radiotherapy is the standard treatment for nasopharyngeal
carcinoma (NPC) [1]. Unfortunately, it can produce unde-
sirable complications after treatment. When radiotherapy is
usedwithcurativeintent,thepossibilityoflatecomplications
in the irradiated tissues must be considered. The spectrum
of malignant neoplasms secondary to radiation of head and
neck tumors is wide. It includes skin, thyroid, and bone
neoplasms. Because radiation ﬁelds for NPC may include
the skull base as well as maxilla, mandible, and pterygoid
bones, radiation-induced osteosarcoma (RIS) can arise from
these sites as one of the late complications of radiotherapy.
These tumors are uncommon but aggressive, occurring after
a latency period of ﬁve years or more following radiotherapy.
Histological proof of sarcoma is necessary to distinguish it
from other radiotherapy changes such as osteonecrosis.
In view of the large number of nasopharyngeal carci-
noma cases, it is not surprising that postirradiation max-
illary, temporal, and sphenoid malignancies are now being
reported. We present a 49-year-old woman with osteosar-
coma of the maxilla occuring 14 years after radiotherapy for
NPC with a review of literature.
2.CaseReport
A 49-year-old woman, treated in 1992 for NPC (T3N1M0)
with radiotherapy (70Gy over 35 sessions with large lateral
opposing faciocervical ﬁelds and complementary anterior
facial ﬁeld), presented fourteen years later with pain and
swelling of the cheek. The swelling was increasing in size and
advancingtowardstheeye.Examinationshowedanexpansile
mass in the right maxillary region with local paresthesia
and proptosis of the right eye. The overlying skin appeared
normal.
Computed tomography (CT) demonstrated a large bony
mass in the right maxilla that extended into temporal bone
(Figure 1). Histological examination disclosed a ﬁbroblastic
osteosarcoma which produced chondroid substance, and
contained distinct osteoid trabeculae. Immunohistochemis-
tery showed diﬀuse positivity to vimentin and S100 protein
antibodies (Figure 2). CT of the lung revealed no lung
metastases.
After discussing the unresectability of the tumor with
the patient, neoadjuvant chemotherapy was proposed with
high-dose methotrexate. The tumor showed clinical and
radiographic progression after 5 cycles of treatment. The2 Journal of Oncology
119
20
-32.0 mm
+21.5D
MR = 1.5
(212, 231)
R
WL = 1412
WW = 462
119:82
X vision/GX
1.0s
S/3
PR/HF/VFH
FC30/US0
TOSHIBA MEC
96.06.14  09:29:54.7
             
                          /F
120 kV/130 mAs
R
WL = 1012
WW = 2589
119:9
X vision/GX
1.0s
S/3
SU/HF/VFF
FC30/ORG
TOSHIBA MEC
96.06.14  09:06:56.1
             
                          /F
120 kV/130 mAs
119
8
-9.0 mm
+0.0D
MR = 1.4
(226, 213)
Figure 1: Bony mass in the left maxilla and extended to the right temporal bone.
Figure 2: Section from the biopsy specimen showing a chondrob-
lastic osteosarcoma which contains dominating chondroid sub-
stance (right side) and osteoid trabeculae derived from neoplastic
cells (center) (He × 185).
mass extended into right orbit, right spheno¨ ıd as well as
the nasal cavity. A remedial treatment was started with
doxorubicin and cisplatin, though CT appearances after
chemotherapy were unchanged. Twelve months later, the
patient is alive without metastases, and we are pursung
palliative chemotherapy with ifosfamide and etoposide.
3. Discussion
The occurence of sarcomas in irradiated tissues is an
uncommonbutwell-documentedlong-termcomplicationof
radiotherapy. The incidence of radiation-induced tumors is
increasing in the oncology population as a result of increased
survival, with improvement in cancer treatment [2–4]. In
the largest study reported in English literature, Liu et al. [2]
described 15 cases of RIS as a late complication of NPC. The
study included 33.3% osteosarcoma of the maxilla, 46.7% of
the mandible and 20% froma mixture of the nasalcavity and
paranasal sinuses. They estimated the incidence of radiation-
induced osteosarcoma in NPC as approximately 0.037% [2].
In 1948, Cahan et al. [5] described 11 cases of sarcomas
arising from irradiated bones. They established four criteria
for the diagnosis of radiation-induced osteosarcoma that
are still valid today: (a) the origin of the neoplasm in the
radiation ﬁeld, (b) the nonmalignant nature of the initial
bone condition (this criteria was modiﬁed by Arlen et al.
[6] : “the tumors developed in bone not known to have a
primarymalignantosteoblasticlesionwhentheradiotherapy
was given”), (c) the histological diagnosis of the neoplasm,
and (d) a relatively long latency period. Our patient fulﬁlled
the above-mentioned criteria.
The average standardized incidence of NPC in Tunisia
in 1998 was 3.5 cases per 100000 males and 1.6 cases per
100000 females. More than 80 new cases of NPC are seen
annually.
The most eﬀective treatment is radiotherapy. The whole
tumor dose delivered is generally 65 to 75Gy. The dose
targets the primary tumor and regional lymphatics, inclusive
of the whole sphenoid body and posterior half of maxilla in
all cases. Some other cases may need further intracavitary
boost irradiation. In view of the large number of cases
treated for this particular malignancy, it is not surprising
that postirradiation sarcomas are now being reported in this
population.
In general, a radiation dose of at least 30Gy is required
for the development of radiation-induced sarcoma [5, 7].
Reported radiation doses vary in this population from 25
to 110Gy, with a median of 45Gy [7]. Our patient received
70Gy.
The latency period between radiotherapy for NPC and
the development of temporal bone tumors ranged from 5 to
30yearswithameanof12.9years[8].Ourpatientdeveloped
the second tumor 14 years after primary radiation therapy.
Although the pathogenesis is unknown, various predis-
posing factors have been suggested [9]. RIS may occur after
megavoltage or orthovoltage radiation, but in the latter case,
the treatment dose is lower and the period of irradiation
is longer [10]. In addition to radiation dose, development
of RIS is probably inﬂuenced by other factors: age of the
patient at radiation exposure, association of chemotherapy,
and genetic predisposition [11].
It is suggested that the patients who harbor mutations
in tumor suppressor genes like p53 and RB1 are more prone
to develop radiation-induced osteosarcoma. Friend et al.
[12] described 8 cases of osteosarcoma with an altered RB
allele. Others have suggested that the lack of RB expressionJournal of Oncology 3
in osteosarcoma and soft tissue sarcoma may be common
since RB gene transcripts were not detected. Moreover, they
consider that lack of of RB gene expression occurred only
after the tumor develops. Nevertheless, radiation-induced
DNA alteration is well demonstrated, so we could consider
that deletion or inactivation of this tumor suppressor gene
may be an important factor for RIS [12] with a relative risk
of RIS 400-fold greater than the general population [13].
The Li-Fraumeni syndrome, von Recklinghausen’s dis-
ease, and other hereditary syndromes have also been iden-
t i ﬁ e da sr i s kf a c t o r sf o rR I S[ 14]. In fact, radiotherapy
delivered for benign diseases such as ﬁbrous dysplasia or
Paget’s disease in the past may lead to RIS [15]. In fact, some
studies have proved that RIS are increased after treatment
of Hodgkin’s lymphoma with radiotherapy. In addition,
radiation therapy given during childhood can also increase
the relative risk of RIS to 30 [11]. Leclercq et al. [11]h a v e
suggestedalsothatadditionofalkylator-basedchemotherapy
to radiotherapy will increase the risk of developing RIS
threefold.
The most common clinical ﬁndings of the head and
neck radiation-induced sarcoma are pain and swelling with
pathological fracture also reported. A soft tissue mass and
bone destruction due to new bone formation are the main
characteristics on radiography and CT. The degree of new
bone formation on CT is variable.
Chondroblastic osteosarcoma of the head and neck
represents 25% of all osteosarcoma of this region with a
low histologic grade encountered in 26% of cases [16]. The
treatment of sarcoma of the maxilla irrespective of etiology
includes radical surgery with adjuvant chemotherapy [16].
For the majority of authors, complete surgical excision
with negative surgical margins is crucial to local control
as well as recurrence-free survival. Some authors have
recommended neoadjuvant chemotherapy before deﬁnitive
surgery is undertaken [17]. The majority of authors in the
reported cases and series use the same chemotherapy as
used for primary sarcoma with ifosfamide, methorexate,
and doxorubicin, though there are no randomised trials to
compare results. Surgery appears to oﬀer the best chance
of cure. However, as osteosarcoma metastasizes by the
hematogenous route, there is rationale for the addition
of adjuvant chemotherapy [4] .T h e r eh a v en o tb e e nl a r g e
studies to determine the eﬀectiveness of various treatments
for postirradiation osteosarcoma.
Tumor size and grade are the two most important
prognostic factors for soft tissue sarcomas, including those
associated with radiation therapy. The treatment of choice
for RIS is surgical resection with negative margins [18]. The
role of adjuvant therapy in radiation-induced sarcomas is
unknown. It seems that there is no survival beneﬁt for those
patients receiving adjuvant chemotherapy or radiotherapy
compared with those treated only with surgery that achieves
negative margins [11–18].
High-grade tumors that are larger than 5cm should be
treated with primary chemotherapy followed by complete
surgical excision of residual disease. All low-grade tumors
and high-grade tumors that are 5cm or smaller should be
treated with a margin-negative surgical excision, and sys-
temic chemotherapy should be considered when a negative
margin is not accomplished [17].
Osteosarcomas of the long bones frequently develop
metastatic tumor, especially to the lungs. In contrast, RIS
of the skull does not exhibit this tendency. Moreover, these
tumors have a poor prognosis because of rapid local growth
[19].
The prognosis of radiation-induced sarcoma is generally
thought to be worse than primary sarcomas, regardless of
site. The cumulative disease-free survival at 5 years for
patients with a postirradiation osteosarcoma was 17%, with
a median survival estimate of 1 year [14]. In a review of 78
cases from the Mayo Clinic, about 30% of the patients with
sarcomas of the craniofacial bones survived 5 years without
recurrence [20].
Most series report overall survival rates at 5 years in the
range of 10% to 30% [14–21]. Several factors predict for
this poor survival rate, including neurosensory symptoms
at presentation, increasing patient age, and surgical margins
lessthan5mm[7–11].Inmultivariateanalysisof160casesof
RIS, Brady et al. [22] demonstrated that three variables had
prognostic signiﬁcance: the presence of metastatic disease,
the completeness of surgical resection in patients with
localized disease, and the size of the primary tumor in
patients who underwent complete resection. Survival was
independent of histologic subtype or site of disease.
Often, there is a delay in diagnosis until an advanced
stage of disease because of the diﬃcult distinction between
neoplastic and radiation changes. In addition, RIS occurs
often in anatomic sites (head and neck, pelvic, thorax) where
complete surgical resection is diﬃcult.
To prevent radiation-induced sarcoma, it is important to
have meticulous attention to radiation dosimetry in carefully
planned ﬁelds. For our case, the current radiation dose is
less than in the past with the addition of chemotherapy in
the treatment of NPC. Furthermore, intensity modulation
radiotherapy (IMRT) will reduce the exposure of normal
tissues to radiation.
Because of the aggressive nature of RIS, careful long-
term follow-up of irradiated patients is crucial. A high
index of suspicion is needed for early detection and timely
intervention.
4. Conclusion
Radiation-induced sarcoma is a potential late sequelae of
radiationtherapy.Thesetumorsareveryaggressiveandoften
elude early detection, thereby hindering timely intervention.
Although early detection of radiation-induced tumors is
important, it is diﬃcult since changes seen after radio-
therapy have often been attributed to other causes such as
osteonecrosis. Although the condition is rare, the possibility
of RIS must be considered in any patient who has received
radiation treatment.
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